Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
17 Jan 2022 | Global | Technology Research
Global Advances in Omics Technologies Enable Future Drug Discovery and Growth Opportunities
Emerging Omics Platforms Drive Precision Drug Discovery
For a long time, drug discovery followed the same path and used conventional analysis methods for proposed targets. Today, changes in technology and the ability to study omics are transforming drug development. Personalized therapy is on the rise and promises to be more effective and efficient in addressing challenges. With growing interest in ...
$4,950.00 -
17 Aug 2022 | Global | Technology Research
Therapeutic Advances in Amyloidosis
Research Efforts and Technology Developments through Partnerships and Collaborations will Push New Therapeutic Modalities into Treatment Regimens.
Amyloidosis is a rare disease caused by the accumulation and the deposition of proteins such as immunoglobulin light-chain protein in AL amyloidosis and misfolded transthyretin (TTR) protein in ATTR amyloidosis. There are a few other types of amyloidosis as well, which are either a result of a preexisting condition or are not highly prevalent. Vari...
$4,950.00 -
29 Aug 2022 | Global | Technology Research
Advancements in miRNA: Technology Assessment
Developments in miRNA sequencing and analysis are driving future growth potential in therapeutics and diagnostics
Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has ...
$4,950.00 -
05 Sep 2022 | Global | Technology Research
Technology Growth Opportunities for Exosome-Mediated Drug Delivery
Exosomes Are Promising Delivery Carriers for Advanced Therapeutics
Exosome-mediated drug delivery is a promising alternative to conventional drug delivery methods, making rapid strides in the biopharmaceutical industry because of the safety and efficacy advantages exosomes offer as nanocarriers over synthetic nanoparticles. The widely explored concepts of nanomedicine, nucleic acid therapeutics, and cell-free vacc...
$4,950.00 -
09 Nov 2022 | Global | Technology Research
Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis
Strategic partnering and new product development will enable better biologics for personalized and targeted treatment
Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies. NMDs prese...
$4,950.00 -
20 Dec 2022 | Global | Technology Research
Advances and Growth Opportunities in RNA Vaccines
Technology Innovations and Investments Bolster Next-generation Prophylactic and Therapeutic RNA Vaccines
RNA therapeutics and vaccines have been around for a long time, but the COVID-19 pandemic enabled their mass-market commercialization. Industry players saw mRNA vaccines developed for COVID-19 as effective for reducing the impact of the SARS-CoV-2 virus in populations. Moderna emerged as the first player to develop and commercialize an mRNA vaccine...
$4,950.00 -
21 Dec 2022 | Global | Technology Research
Antibody-drug Conjugates: Technology Growth Opportunities
Disruptive Technologies and a Conducive Funding Environment are Fostering Growth
Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further ...
$4,950.00
